There is little doubt that Vertex Pharmaceuticals Inc.’s cystic fibrosis transmembrane conductance regulator (CFTR) modulators Orkambi (lumacaftor/ivacaftor) and Kalydeco (ivacaftor) have changed the face of treatment for cystic fibrosis patients. With the approval of Symdeko (tezacaftor), the base therapy for a triple combination with next-generation CFTR modulators, Vertex’s rule of what is forecast to be an $8.6bn market by 2025 is clear for the foreseeable future.
Vertex’s control of the CF market using its triple combination of CFTR modulators is set to carry on for at...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
